Privium Fund Management B.V. lowered its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 17.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 97,154 shares of the biopharmaceutical company's stock after selling 20,829 shares during the period. Intra-Cellular Therapies makes up approximately 1.8% of Privium Fund Management B.V.'s portfolio, making the stock its 13th largest position. Privium Fund Management B.V. owned about 0.09% of Intra-Cellular Therapies worth $8,114,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Xponance Inc. lifted its holdings in shares of Intra-Cellular Therapies by 4.8% in the 4th quarter. Xponance Inc. now owns 13,609 shares of the biopharmaceutical company's stock worth $1,137,000 after acquiring an additional 628 shares during the last quarter. Natixis Advisors LLC grew its stake in shares of Intra-Cellular Therapies by 2.0% in the fourth quarter. Natixis Advisors LLC now owns 25,085 shares of the biopharmaceutical company's stock valued at $2,095,000 after buying an additional 502 shares in the last quarter. Swiss National Bank raised its holdings in shares of Intra-Cellular Therapies by 0.8% in the 4th quarter. Swiss National Bank now owns 187,000 shares of the biopharmaceutical company's stock valued at $15,618,000 after buying an additional 1,500 shares during the period. HighTower Advisors LLC raised its holdings in shares of Intra-Cellular Therapies by 9.1% in the 4th quarter. HighTower Advisors LLC now owns 4,179 shares of the biopharmaceutical company's stock valued at $349,000 after buying an additional 350 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Intra-Cellular Therapies by 9.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,639 shares of the biopharmaceutical company's stock worth $2,058,000 after acquiring an additional 2,117 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.
Intra-Cellular Therapies Stock Up 0.0 %
Shares of ITCI traded up $0.05 on Friday, hitting $131.65. 1,836,929 shares of the stock traded hands, compared to its average volume of 1,339,146. The firm has a market capitalization of $14.00 billion, a P/E ratio of -151.32 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.67. The stock's 50 day moving average is $128.61 and its two-hundred day moving average is $97.59.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. Research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.
Analyst Ratings Changes
A number of analysts have issued reports on the stock. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research note on Thursday. They set a "hold" rating on the stock. Royal Bank of Canada restated a "sector perform" rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Mizuho cut shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and cut their target price for the company from $140.00 to $132.00 in a report on Monday, February 24th. Needham & Company LLC reissued a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Finally, Baird R W downgraded shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Ten research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $106.08.
Check Out Our Latest Report on ITCI
About Intra-Cellular Therapies
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
See Also
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
